Every July, the pathology and oncology community marks Sarcoma Awareness Month - a time dedicated to shining light on one of the most misunderstood cancers out there. Often called the "forgotten cancer," sarcoma makes up only about 1% of adult cancers, yet it accounts for 15–20% of cancers in children. With over 70 distinct subtypes arising from bone, muscle, fat, nerve, and blood vessel tissue, sarcoma is a diagnostic puzzle even for experienced pathologists.
This awareness month is a good moment to talk about why that puzzle is so hard to solve-and how the right diagnostic tools make all the difference.
Why Sarcoma Is So Difficult to Diagnose
Sarcomas often start quietly: a painless lump, mild swelling, or vague bone pain that's easy to dismiss. By the time patients seek specialized care, the tumor's exact subtype still needs to be pinned down - and under a microscope, many sarcoma subtypes can look deceptively similar despite behaving very differently and requiring different treatment approaches.
This is where immunohistochemistry (IHC) becomes essential. A well-chosen antibody panel helps pathologists move beyond morphology alone and confirm the precise cell lineage a tumor is arising from.
How Antibodies Help Narrow Down the Diagnosis
Rather than relying on a single test, pathologists use a panel of antibodies to build confidence in a diagnosis. For instance, Desmin and MyoD1 help confirm muscle-based tumors like rhabdomyosarcoma, while a vascular marker like CD31 points toward tumors arising from blood vessel lining, such as angiosarcoma. In some cases, it's the absence of a marker that matters most - loss of INI1 expression, for example, is a hallmark finding in epithelioid sarcoma.
Our Soft Tissue panel is built around markers like these, giving labs the flexibility to work through a broad differential without guesswork.
Why This Matters Beyond the Lab
Getting the subtype right isn't just an academic exercise. It shapes the entire treatment path - from surgical margins to whether a patient qualifies for newer targeted or biomarker-driven therapies now emerging in sarcoma care. An accurate, timely diagnosis can be the difference between a treatable case and a missed window.
At PathnSitu Biotechnologies, we make diagnostic markers that help pathologists accurately detect and diagnose sarcomas.
